Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

Abstract Background Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of chemotherapy are desirable. Poly-ADP-Ribose Polymerase inhibitors (PARPi) have...

Full description

Bibliographic Details
Main Authors: Pietro Paolo Vitiello, Giulia Martini, Luigi Mele, Emilio Francesco Giunta, Vincenzo De Falco, Davide Ciardiello, Valentina Belli, Claudia Cardone, Nunzia Matrone, Luca Poliero, Virginia Tirino, Stefania Napolitano, Carminia Della Corte, Francesco Selvaggi, Gianpaolo Papaccio, Teresa Troiani, Floriana Morgillo, Vincenzo Desiderio, Fortunato Ciardiello, Erika Martinelli
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Colorectal cancer
DNA damage response
Homologous recombination
Combination treatment
Chemopotentiation
Synergism
Online Access:https://doi.org/10.1186/s13046-020-01811-8

Internet

https://doi.org/10.1186/s13046-020-01811-8

Similar Items